SEC Comment Letter 0000000000-25-003866 to CERENOME, INC. (PSTV)

CERENOME, INC.
Date: April 11, 2025 · CIK: 0001095981 · Accession: 0000000000-25-003866

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-34375

Date

April 11, 2025

Author

Finance

Form

UPLOAD

Company

CERENOME, INC.

Letter

Re: Plus Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 14, 2025 File No. 001-34375 Dear Marc H. Hedrick:

April 11, 2025

Marc H. Hedrick President and Chief Executive Officer Plus Therapeutics, Inc. 2710 Reed Rd, Suite 160 Houston, TX 77051

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: William Intner, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 11, 2025

Marc H. Hedrick
President and Chief Executive Officer
Plus Therapeutics, Inc.
2710 Reed Rd, Suite 160
Houston, TX 77051

 Re: Plus Therapeutics, Inc.
 Preliminary Proxy Statement on Schedule 14A
 Filed March 14, 2025
 File No. 001-34375
Dear Marc H. Hedrick:

 We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
cc: William Intner, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io